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We are presenting a case of an adult male patient with monocytic acute myeloid leukemia
(AML) who had on presentation brain infarction and bilobed nuclei had been demonstrated in
many of the leukemic blasts. There was no laboratory evidence of acute disseminated intravas-
cular coagulopathy, on presentation or later on. Initially the diagnosis of acute promyelocytic
leukemia (APL) was considered, so all trans-retinoic acid (ATRA) was added to induction chemo
therapy. As the diagnosis of APL was ruled out, based on the flow cytometry, fluorescent in situ
hybridization and polymerase chain reaction findings, the ATRA was discontinued and the
patient continued on the standard AML chemo therapy induction regimen. Later on chromoso-
mal analysis was also normal. Sever dehydration on presentation, would have contributed to
brain infarction. AML particularly monocytic, can mimic APL, especially its microgranular vari-
ant. The possible ATRA therapy side effects, can be avoided by early confirmation of the diag-
nosis.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).A 48-year-old man with unremarkable medical history
presented with fatigability, decreased vision in one eye,
and severe dehydration. Complete blood count test gave
the following measurements: white blood cells 74.6  109/
L, neutrophils 6%, lymphocytes 9%, hemoglobin 11 g/dL,
Figure 1 Bone marrow aspirate: blasts some showing bilobed
nuclei.
Figure 2 Plain brain computed tomography showing posterior
cerebral artery infarction.
AML Mimicking APL 117platelets 87  109/L, with 73% blasts, some of which had
bilobed nuclei. Results of initial coagulation tests were as
follows: prothrombin time 14.8 seconds (11.5–15 seconds),
activated partial thromboplastin time 35.5 seconds
(28–41 seconds), and fibrinogen 5.5 g/L (1.4–4.4 g/L). The
bone marrow aspirate was hypercellular with 90% blasts,
many of which showed bilobed nuclei reminiscent of
microgranular acute promyelocytic leukemia (APL)
(Figure 1). Brain computed tomography showed acute left
posterior cerebral artery infarction (Figure 2). Considering
the blasts with bilobed nuclei and the brain infarction,
APL was suspected. Accordingly, all trans-retinoic acid
(ATRA) was added to the induction chemotherapy regimen.
On flow cytometry, the blasts were positive for CD34,
CD13, CD33, CD64, CD11c, CD117, HLA-DR, CD4, andmyeloperoxidase (30% of cells). Fluorescence in situ
hybridization (FISH) study result was negative for PML/RARa
rearrangement, and this was also confirmed by polymerase
chain reaction. Based on these findings, APL was ruled
out, and thus, ATRA was discontinued. The patient then
continued on the standard chemotherapy induction regimen
for non-APL acute myeloid leukemia (AML). Other FISH
studies on the bone marrow aspiration showed no evidence
of any of the following: t(9;22), t(8;21) translocations, CBFB
or MLL gene rearrangements, 5q31 (EGR1) or 7q31 (D7S522)
deletions, or trisomy of chromosome 8. Chromosomal
analysis on the bone marrow aspirate revealed 46, XY, a
normal male karyotype with no apparent numerical or
structural abnormalities.
In the absence of APL and disseminated intravascular
coagulation, severe dehydration could have contributed to
the brain infarction [1].
AML cases, particularly monocytic leukemia can mimic
APL, a microgranular variant. This has been reported in
AML with t(8;16) and under other circumstances [2,3]. This
may lead to adding ATRA to the initial treatment regimen,
whose possible toxicity is well-known. Thus, early confirma-
tion by flow cytometry, FISH, and molecular studies for
PML/RARa rearrangement would help in avoiding such side
effects [4].
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